HealthItCare.com maps telehealth and pharmacy offers for semaglutide, tirzepatide, and related GLP-1 care. We organize what each program publishes about eligibility, brand-name versus compounded supply, monthly cost, and who manages your follow-up so you can read the tradeoffs before a consult.
TrimRx
From $149/mo
HealthItCare.com is a directory, not a clinic. The listings above show how programs are sold. The pages below unpack why people shop these offers, what published outcomes can and cannot tell you, how GLP-1 care is usually structured, and what to verify before you enroll with any provider.
Interest in GLP-1 weight care did not appear overnight. Brand-name pens still carry high cash-pay list prices, prior-authorization queues remain long, and a growing set of telehealth groups now publish a monthly number that includes a consult plus a shipped supply. People compare those offers because the old path — wait for coverage, or pay more than a thousand dollars out of pocket — is not a path they can use.
This site treats that shopping as a commercial decision sitting next to a medical one. A listing can explain the bundle. Only a licensed clinician can decide whether a medicine is appropriate.
Branded GLP-1 medicines have published trial averages that many readers treat as a forecast. Those averages describe groups, not a person. Some participants lost a large share of body weight. Others lost less, stopped because of gastrointestinal effects, or regained after the drug was discontinued. Compounded preparations sold in 2026 telehealth funnels are not the same evidence package as an FDA-approved pen.
What people often report, when a program is a match, is quieter hunger, smaller portions that feel sufficient, and slower eating. Side effects can include nausea, constipation, diarrhea, and fatigue, especially during dose increases. None of that is a promise HealthItCare.com can make, and none of it replaces a conversation about pancreatitis history, thyroid risk, pregnancy plans, or other medicines you already take.
Most 2026 consumer offers follow a similar sequence even when the branding looks different. You complete an intake. A licensed clinician reviews history and, if they prescribe, sends an order to a pharmacy. The pharmacy ships a brand-name pen or a compounded vial. You inject on a schedule, report how you feel, and the dose may rise. Labs, when they exist, should happen before the first shipment — not after you have already paid for a month you cannot use.
Starting dose, titration speed, and whether the supply is branded or compounded should follow the person in front of the clinician: other drugs, kidney and gallbladder history, how hard the last increase hit, and whether the goal is obesity care, diabetes care, or both. A program that uses one script for every new account is selling a subscription. A program that names who adjusts the dose when you stall is selling follow-up.
Two ads can quote a similar starter price and still be different products. One funnel may be a membership that still sends you to a retail brand pen. Another may be compounded semaglutide or a GLP-1 + GIP combination with a short consult. Read the supply line, the pharmacy identity, and the follow-up owner before you compare the monthly number.
Use the listing row on this page as a briefing: price, what is included, and a visit link. Then open the provider’s own checkout and confirm that the 2026 page still matches what they show you after the quiz.
The 2026 telehealth model is simple on paper: intake on a phone, video or async review, shipped medication, and messaging for side effects. The version that works is the one that still names a medical group, a pharmacy, and a human who can change the dose. Unlimited 24/7 support, when a program actually staffs it, matters more than a polished quiz.
You should still be able to take the paperwork to your own clinician. A listing site cannot see your chart. If anything in the intake feels rushed, pause. GLP-1 medicines are not a checkout add-on.
No. We publish comparisons and educational copy. Any consult, prescription, or pharmacy fill happens between you, a licensed clinician, and the provider you choose. Partner links, including Visit Site buttons, may be compensated.
No. Compounded products are not FDA-approved copies of Wegovy, Ozempic, Zepbound, or Mounjaro. Formulas, salts, and pharmacy practices differ. Treat compounded and brand-name offers as different products, not as a discount on the same one.
Often not. Many 2026 cash-pay telehealth offers sit outside the pharmacy benefit. Some people use HSA or FSA funds. Coverage for obesity-labeled brand pens is plan-specific and still commonly needs prior authorization.
There is no honest universal timeline. Dose ramps take weeks. Appetite change, if it happens, does not arrive on a schedule you can buy. Anyone guaranteeing a number of pounds by a calendar date is selling urgency, not care.
Ask the program, in writing, who lowers or pauses the dose and whether unused supply is refundable. If the only answer is a chatbot, that is part of the comparison.